Drug intelligence / Profile preview

ru he san

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Ru He San is a traditional Chinese medicine formulation primarily used for the treatment of breast lumps or nodules. The product contains Tulipa edulis as its main ingredient and is reported to have mild toxicity, with potential adverse effects such as gastrointestinal discomfort if used excessively or over long periods. Its mechanism of action is not well characterized in Western pharmacology, but it is traditionally believed to resolve phlegm and dissipate masses according to Chinese medicine principles[1].

Other names: ru he san jie pian

Beyond the preview

Go deeper on ru he san.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ru he san.

Explore the full profile